Literature DB >> 29188530

Histopathological vascular investigation of the peritumoral brain zone of glioblastomas.

Ryota Tamura1, Kentaro Ohara2, Hikaru Sasaki1, Yukina Morimoto1, Kazunari Yoshida1, Masahiro Toda3.   

Abstract

To date, no histopathological vascular investigation focusing on peritumoral brain zone (PBZ) has been reported for glioblastoma. We analyzed 10 newly diagnosed cases of glioblastomas. For these PBZs, histopathological investigation was performed by hematoxylin-eosin (H&E) staining and immunohistochemistry was analyzed for CD31, CD34, Factor VIII, VEGF, VEGFR-1/2, Ki67, p53 and nestin. Although it was difficult to identify PBZ by H&E, Ki67 and p53 staining, there were apparent differences in nestin staining among PBZ, tumor core (TC), and normal zone (NZ). Therefore, in this study, we divided PBZ from TC and NZ by nestin staining. Differences in histological features, microvessel density, expression of VEGF and its receptors were assessed for PBZ, TC and NZ. The microvessel density, as determined by counting CD31, CD34 and VEGF receptors, and VEGF-A expression were lower in PBZ than TC. The expression patterns for CD31, CD34 and VEGF receptors in vessels show dissociation in PBZ. In addition, the vascular characteristics of the PBZ may correlate with findings of radiographic imaging. We provide the first clinicopathological evidence that PBZ exhibits unique angiogenic characteristics. These in situ observations will help to elucidate the mechanisms of tumor recurrence.

Entities:  

Keywords:  CD34; Nestin; Peritumoral; VEGF-A; VEGFR

Mesh:

Substances:

Year:  2017        PMID: 29188530     DOI: 10.1007/s11060-017-2648-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Authors:  Markku Miettinen; Maarit-Sarlomo Rikala; Janusz Rys; Jerzy Lasota; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.

Authors:  Mats Hellström; Li-Kun Phng; Jennifer J Hofmann; Elisabet Wallgard; Leigh Coultas; Per Lindblom; Jackelyn Alva; Ann-Katrin Nilsson; Linda Karlsson; Nicholas Gaiano; Keejung Yoon; Janet Rossant; M Luisa Iruela-Arispe; Mattias Kalén; Holger Gerhardt; Christer Betsholtz
Journal:  Nature       Date:  2007-01-28       Impact factor: 49.962

3.  Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours.

Authors:  Y Yao; T Kubota; K Sato; R Kitai; H Takeuchi; H Arishima
Journal:  Acta Neurochir (Wien)       Date:  2001       Impact factor: 2.216

4.  Expression of VEGF and its receptors in different brain tumors.

Authors:  Hongguang Huang; Janka Held-Feindt; Ralf Buhl; Hubertus M Mehdorn; Rolf Mentlein
Journal:  Neurol Res       Date:  2005-06       Impact factor: 2.448

5.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Authors:  Lionel M L Chow; Raelene Endersby; Xiaoyan Zhu; Sherri Rankin; Chunxu Qu; Junyuan Zhang; Alberto Broniscer; David W Ellison; Suzanne J Baker
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

Authors:  Tracy T Batchelor; Elizabeth R Gerstner; Kyrre E Emblem; Dan G Duda; Jayashree Kalpathy-Cramer; Matija Snuderl; Marek Ancukiewicz; Pavlina Polaskova; Marco C Pinho; Dominique Jennings; Scott R Plotkin; Andrew S Chi; April F Eichler; Jorg Dietrich; Fred H Hochberg; Christine Lu-Emerson; A John Iafrate; S Percy Ivy; Bruce R Rosen; Jay S Loeffler; Patrick Y Wen; A Greg Sorensen; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

7.  Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes.

Authors:  Chuzhao Lin; Richard McGough; Bassam Aswad; Joel A Block; Richard Terek
Journal:  J Orthop Res       Date:  2004-11       Impact factor: 3.494

8.  Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.

Authors:  Yohei Kitamura; Hikaru Sasaki; Tokuhiro Kimura; Tomoru Miwa; Satoshi Takahashi; Takeshi Kawase; Kazunari Yoshida
Journal:  J Neuropathol Exp Neurol       Date:  2013-09       Impact factor: 3.685

9.  Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.

Authors:  Pascal O Zinn; Bhanu Mahajan; Bhanu Majadan; Pratheesh Sathyan; Sanjay K Singh; Sadhan Majumder; Ferenc A Jolesz; Rivka R Colen
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

10.  Histopathological investigation of glioblastomas resected under bevacizumab treatment.

Authors:  Ryota Tamura; Toshihide Tanaka; Keisuke Miyake; Yusuke Tabei; Kentaro Ohara; Oltea Sampetrean; Maya Kono; Katsuhiro Mizutani; Yohei Yamamoto; Yuichi Murayama; Takashi Tamiya; Kazunari Yoshida; Hikaru Sasaki
Journal:  Oncotarget       Date:  2016-08-09
View more
  7 in total

1.  Transcriptome profiling reveals PDZ binding kinase as a novel biomarker in peritumoral brain zone of glioblastoma.

Authors:  Banavathy S Kruthika; Ruchi Jain; A Arivazhagan; R D Bharath; T C Yasha; Paturu Kondaiah; Vani Santosh
Journal:  J Neurooncol       Date:  2018-11-20       Impact factor: 4.130

2.  Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.

Authors:  Ryota Tamura; Yukina Morimoto; Kenzo Kosugi; Mizuto Sato; Yumiko Oishi; Ryo Ueda; Ryogo Kikuchi; Hideaki Nagashima; Tetsuro Hikichi; Shinobu Noji; Yutaka Kawakami; Hikaru Sasaki; Kazunari Yoshida; Masahiro Toda
Journal:  BMC Cancer       Date:  2020-03-12       Impact factor: 4.430

3.  The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab.

Authors:  Bruno Carvalho; José Manuel Lopes; Roberto Silva; Joana Peixoto; Dina Leitão; Paula Soares; Ana Catarina Fernandes; Paulo Linhares; Rui Vaz; Jorge Lima
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

Review 4.  Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions.

Authors:  Peter Solar; Michal Hendrych; Martin Barak; Hana Valekova; Marketa Hermanova; Radim Jancalek
Journal:  Front Cell Neurosci       Date:  2022-07-15       Impact factor: 6.147

5.  Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy.

Authors:  António G P Bastos; Bruno Carvalho; Roberto Silva; Dina Leitão; Paulo Linhares; Rui Vaz; Jorge Lima
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

6.  In Vitro and In Vivo Inhibitory Effect of Gujin Xiaoliu Tang in Non-Small Cell Lung Cancer.

Authors:  Chao Hou; Dai-Han Zhou; Yong-Jian Wu; Xiao-Jun Dai; Qing-Ying Wang; Yin-Qiu Wu; En-Xin Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-09       Impact factor: 2.629

7.  DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study.

Authors:  Vera C Keil; Gerrit H Gielen; Bogdan Pintea; Peter Baumgarten; Angeliki Datsi; Kanishka Hittatiya; Matthias Simon; Elke Hattingen
Journal:  Clin Neuroradiol       Date:  2021-04-26       Impact factor: 3.649

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.